Law firms Hagens Berman and Scott+Scott announce collaboration – Business Wire

If you have purchased or otherwise acquired Vaxart, Inc. securities between June 25, 2020, and July 25, 2021, and suffered losses exceeding $100,000, you may be eligible to be a member of the class action. In order to exclude yourself from the class action lawsuit, you must submit a written request. This request must include your name, address, phone number, email address, and the quantity and purchase price of your Vaxart securities.

There are three methods by which you can submit your exclusion request. The first option is to mail your request to Vaxart’s designated exclusion processor. This can be done by sending your request, along with all required details, to the specified mailing address. Ensure that your request is postmarked by the deadline to be considered valid.

Another way to request exclusion is by completing and submitting the online form on Vaxart’s exclusion website. This form will require you to provide the necessary information, such as your contact details and the relevant data regarding your Vaxart securities purchases. By submitting the form online before the deadline, your exclusion request will be considered valid and processed accordingly.

The third method available for submitting exclusion requests is to contact Vaxart’s exclusion hotline. By calling the designated hotline number, you can provide the required information over the phone to complete your exclusion request. Make sure to call within the specified timeframe to ensure that your request is considered valid.

It is important to note that exclusion requests that fail to comply with the specified requirements or deadlines will not be considered valid. Therefore, it is crucial that you provide accurate and complete information in your request and submit it through one of the designated channels in a timely manner. By following the outlined procedures for submitting exclusion requests, you can effectively exclude yourself from the class action lawsuit involving Vaxart, Inc. securities litigation.